Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis.British journal of cancer · 2026
   Pooled it
2. Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers.Frontiers in oncology · 2022
   Pooled it
3. Mainstreaming genetics and genomics: a systematic review of the barriers and facilitators for nurses and physicians in secondary and tertiary care.Genetics in medicine : official journal of the American College of Medical Genetics · 2020
   Pooled it
4. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
   Trial
5. Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy.Molecular diversity · 2025
   Review
6. DNA Damage and Its Role in Cancer Therapeutics.International journal of molecular sciences · 2023
   Review
7. Mainstreaming of genomics in oncology: a nationwide survey of the genomics training needs of UK oncologists.Clinical medicine (London, England) · 2023
   Article
8. A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.Molecular biology reports · 2022
   Review
9. Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery.Cancers · 2022
   Review
10. Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.Cancers · 2021
    Review
11. PathogenicCancers · 2021
    Review
12. Identification of Eleven NovelFrontiers in oncology · 2021
    Article
13. Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New HInternational journal of molecular sciences · 2020
    Review
14. Exploring six-coordinate germanium(IV)-diketonate complexes as anticancer agents.Inorganica chimica acta · 2020
    Article
15. Bilateral Triple Negative Invasive Ductal Breast Carcinoma in aTaehan Yongsang Uihakhoe chi · 2020
    Article
16. A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics.International journal of molecular sciences · 2020
    Review
17. Genomic Profiling Comparison of GermlineFrontiers in oncology · 2020
    Article
18. Identification of NovelFrontiers in genetics · 2020
    Article
19. Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer.Frontiers in oncology · 2019
    Review
20. Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.Therapeutic advances in medical oncology · 2019
    Review

Corrections and comments

• Comment on
  Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as